HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Karin Vanderkerken Selected Research

Bone Diseases (Bone Disease)

7/2009Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
3/2009Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
12/2008Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
10/2007Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
5/2007Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
4/2007Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
1/2007An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
8/2004Evidence of a role for RANKL in the development of myeloma bone disease.
3/2003Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
2/2003Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Karin Vanderkerken Research Topics

Disease

33Multiple Myeloma
08/2015 - 01/2002
26Neoplasms (Cancer)
04/2015 - 01/2002
11Bone Diseases (Bone Disease)
07/2009 - 01/2003
4Neoplasm Metastasis (Metastasis)
01/2014 - 09/2004
4Anoxia (Hypoxia)
09/2013 - 06/2005
3Bone Resorption
12/2008 - 01/2007
2Hematologic Neoplasms (Hematological Malignancy)
01/2013 - 09/2006
2Osteolysis
01/2006 - 03/2003
1Drug Toxicity (Drug Safety)
12/2013
1Graft vs Host Disease (Graft-Versus-Host Disease)
02/2012
1Inflammation
11/2010
1Anemia
11/2010
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2010
1Disease Progression
04/2003

Drug/Important Bio-Agent (IBA)

6Insulin (Novolin)FDA Link
04/2012 - 01/2006
5Histone Deacetylase InhibitorsIBA
02/2015 - 07/2009
4Proteasome Endopeptidase Complex (Proteasome)IBA
08/2015 - 07/2008
4bortezomib (Velcade)FDA Link
09/2013 - 07/2008
4OsteoprotegerinIBA
01/2007 - 01/2003
3DNA (Deoxyribonucleic Acid)IBA
02/2015 - 01/2013
3CytokinesIBA
07/2014 - 01/2013
3picropodophyllinIBA
04/2012 - 01/2006
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
07/2014 - 05/2007
2ChemokinesIBA
01/2014 - 05/2006
2vorinostat (suberoylanilide hydroxamic acid)FDA Link
12/2013 - 05/2013
2TH 302IBA
09/2013 - 09/2010
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2012 - 01/2006
2thymosin beta(4)IBA
04/2010 - 01/2010
2RANK LigandIBA
01/2007 - 01/2003
2Chemokine ReceptorsIBA
02/2006 - 01/2006
2Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA
08/2004 - 01/2003
2zoledronic acid (zoledronate)FDA Link
03/2003 - 02/2003
1Fluorouracil (Carac)FDA LinkGeneric
04/2015
1AntibodiesIBA
04/2015
1Carbon MonoxideIBA
11/2014
1decitabine (5-aza-2'-deoxycytidine)FDA Link
05/2014
1Histone Deacetylases (Histone Deacetylase)IBA
05/2013
1Drug CombinationsIBA
01/2013
1Immunologic Factors (Immunomodulators)IBA
01/2013
1Cytochrome P-450 CYP1A1 (CYP1A1)IBA
11/2012
1sorafenib (BAY 43-9006)FDA Link
10/2012
1Proteins (Proteins, Gene)IBA
06/2012
1Cadherins (E-Cadherin)IBA
06/2012
1Phosphotransferases (Kinase)IBA
04/2012
1tyrosine receptor (receptor, tyrosine)IBA
04/2012
1Caspase 3 (Caspase-3)IBA
02/2012
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
02/2012
1activin AIBA
12/2010
1Bone Morphogenetic Protein 2IBA
11/2010
1hepcidinIBA
11/2010
1HormonesIBA
11/2010
1IronIBA
11/2010
1Hemoglobins (Hemoglobin)IBA
11/2010
1Insulin-Like Growth Factor I (IGF-1)IBA
03/2010
1Purine-Nucleoside PhosphorylaseIBA
01/2010
1deoxyguanosine triphosphate (dGTP)IBA
01/2010
1LBH589IBA
01/2010
1immucillin HIBA
01/2010
1ThymosinIBA
01/2010
1JNJ 26481585IBA
07/2009
1iodonitrotetrazolium (INT)IBA
03/2009
12- (3- pyridinyl)- 1- hydroxyethylidene- 1,1- phosphonocarboxylic acidIBA
12/2008
1Geranylgeranyltransferase type IIIBA
12/2008
1Rab geranylgeranyl transferase beta-subunitIBA
12/2008
1Immunoglobulins (Immunoglobulin)IBA
11/2008
16- acetyl- 8- cyclopentyl- 5- methyl- 2- (5- piperazin- 1- ylpyridin- 2- ylamino)- 8H- pyrido(2,3- d)pyrimidin- 7- oneIBA
07/2008
1Cyclin D2IBA
07/2008
1SCIO-469IBA
05/2007
1Mitogen-Activated Protein Kinase 14IBA
05/2007
1Alendronate (Alendronate Sodium)FDA LinkGeneric
04/2007
1apomine (SR 45023A)IBA
04/2007
1EstersIBA
04/2007
1goralatideIBA
09/2006
1OsteopontinIBA
02/2006
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
01/2006
1Biological Markers (Surrogate Marker)IBA
06/2005
1pimonidazoleIBA
06/2005
1Matrix MetalloproteinasesIBA
09/2004
1Dexamethasone (Maxidex)FDA LinkGeneric
04/2003
1DiphosphonatesIBA
02/2003
1ibandronic acid (Boniva)FDA Link
02/2003
1Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA
01/2003
1Actins (F Actin)IBA
11/2002
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
01/2002
1Peptide Hydrolases (Proteases)IBA
01/2002
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2002
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2002

Therapy/Procedure

1Immunomodulation
02/2015
1Hematopoietic Stem Cell Transplantation
02/2012
1Heterologous Transplantation (Xenotransplantation)
07/2008